Renal Cell Carcinoma: Genetics, Surgical Management, and Systemic Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 15 March 2026 | Viewed by 1052
Special Issue Editors
Interests: robotics; renal cell cancer; tumor thrombi
Interests: global health; renal cell carcinoma; open surgery
Special Issue Information
Dear Colleagues,
Renal cell carcinoma is the most common type of kidney cancer and accounts for approximately 2% of all cancer cases worldwide every year. Mortality rates are now estimated at nearly 200,000 people per year. Its management is multidisciplinary, often involving urology, nephrology, and medical oncology, among other specialisms. Further, there are more options now than ever before for treating patients afflicted with this disease. Traditional modalities such as surgery remain the mainstay in many settings; however, less invasive interventional options such as cryotherapy and ablation are also available. Additionally, systemic therapy has revolutionized treatment outcomes for renal cell carcinoma patients, but there is room for further innovation. Lastly, discoveries at the genetic level have provided practitioners with a wealth of information on how the disease can be caused and targeted. For this Special Issue, we invite papers from a variety of backgrounds on topics including, but not limited to, the genetics, surgical outcomes, systemic therapy, and social disparities of the disease.
Dr. Alejandro Remigio Rodríguez
Prof. Dr. Stênio C. Zequi
Guest Editors
Dr. Maxwell Sandberg
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cell carcinoma
- robotics
- laparoscopy
- systemic therapy
- genetics
- surgery
- urology
- disparities
- tumor thrombus
- cryotherapy
- global health
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
